e-learning
resources
Barcelona 2010
Sunday, 19.09.2010
COPD: phenotyping and monitoring
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency
R. Carter, A. Dirksen, E. Piitulainen, R. Stockley (United Kingdom; Hellerup, Denmark; Malmö, Sweden)
Source:
Annual Congress 2010 - COPD: phenotyping and monitoring
Session:
COPD: phenotyping and monitoring
Session type:
Thematic Poster Session
Number:
1307
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Carter, A. Dirksen, E. Piitulainen, R. Stockley (United Kingdom; Hellerup, Denmark; Malmö, Sweden). Aα360: A measure of disease and treatment efficacy in alpha-1-antitrypsin (A1AT) deficiency. Eur Respir J 2010; 36: Suppl. 54, 1307
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Investigating change in the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD)
Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases
Year: 2011
Severe alpha-1-antitrypsin deficiency (A1ATD) caused by Q0
Ourém
mutation: A clinical characterization
Source: Annual Congress 2010 - Genetics of obstruction
Year: 2010
Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD.
Source: Virtual Congress 2021 – COPD burden, epidemiology and management
Year: 2021
Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD).
Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases
Year: 2021
Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Erythrocyte abnormalities in alpha-1-antitrypsin deficiency (AATD) patients
Source: Annual Congress 2009 - COPD: exacerbation and clinical problems
Year: 2009
Alpha 1 antitrypsin (A1AT) deficiency among patients with cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 501s
Year: 2003
Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease.
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019
Intra-epithelial polymerization, accumulation and secretion of alpha
1
antitrypsin (AAT) Z polymers in the lung of patients with alpha-1 antitrypsin deficiency (AATD)
Source: Annual Congress 2010 - Epithelial cell biology
Year: 2010
Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough
Source: Eur Respir J 2016; 47: 35-38
Year: 2016
Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ)
Source: Eur Respir J 2006; 28: Suppl. 50, 144s
Year: 2006
Alpha 1 - antitrypsin deficiency: diagnosis and treatment
Source: Virtual Congress 2021 – Alpha 1 - antitrypsin deficiency: diagnosis and treatment
Year: 2021
Alpha-1-antitrypsin deficiency
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=139
Year: 2005
Characterization of a population of alpha
1
-antitrypsin deficient (A
1
ATD) patients
Source: Annual Congress 2008 - COPD
Year: 2008
Health status changes in alpha-1-antitrypsin deficiency (PiZ phenotype) over 3 years
Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD
Year: 2003
Occupational exposure in alpha-1-antitrypsin deficiency (AATD)
Source: Annual Congress 2008 - COPD and other environment-related lung diseases
Year: 2008
Effect of serum alpha-1-antitrypsin (AAT) and alpha-2-macroglobulin (AMG) levels on sputum conversion in active pulmonary tuberculosis
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008
Short-term variability of biomakers of proteinase activity in patients with emphysema associated with type Z alpha-1-antitrypsin deficiency
Source: Eur Respir J 2004; 24: Suppl. 48, 459s
Year: 2004
Effects of double dose alpha 1 antitrypsin (AAT) therapy on cytokine pathways in AAT Deficiency (AATD)
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept